A phase Ib clinical trial to evaluate the safety, tolerability and pharmacokinetic characteristics of LZM005 combined with trastuzumab and docetaxel in the treatment of advanced breast cancer
Latest Information Update: 24 Oct 2024
Price :
$35 *
At a glance
- Drugs LZM 005 (Primary) ; Docetaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 08 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology